DBV Technologies S.A. (NASDAQ:DBVT) Stock Has Average Target Price of $48.50

DBV Technologies S.A. (NASDAQ:DBVT) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $48.50.

A number of analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of DBV Technologies in a research note on Thursday, September 10th. Citizens Jmp upped their target price on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 30th. Weiss Ratings lowered shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Finally, Wall Street Zen lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 4th.

DBV Technologies Stock Performance

DBV Technologies stock opened at $11.60 on Friday. The stock’s 50 day moving average price is $13.58 and its 200 day moving average price is $16.92. The firm has a market capitalization of $729.41 million, a PE ratio of -3.30 and a beta of -0.95. DBV Technologies has a one year low of $8.85 and a one year high of $26.18.

Institutional Trading of DBV Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of DBVT. ADAR1 Capital Management LLC acquired a new stake in DBV Technologies in the first quarter valued at $21,159,000. Perceptive Advisors LLC bought a new position in DBV Technologies during the 1st quarter valued at $20,146,000. Elmind Capital LP acquired a new position in DBV Technologies during the 1st quarter worth $5,536,000. Vivo Capital LLC increased its position in shares of DBV Technologies by 8.4% in the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after purchasing an additional 205,943 shares during the last quarter. Finally, Dorsey Wright & Associates bought a new stake in shares of DBV Technologies in the 1st quarter worth about $2,142,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies’ primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.